Genes regulated in MPTP-treated macaques and human Parkinson's disease suggest a common signature in prefrontal cortex

Neurobiology of Disease

Volumn 38, Issue 3, 2010, Pages 386-394

  Storvik, Markus ^a   Arguel, Marie Jeanne ^b,c   Schmieder, Sandra ^b   Delerue Audegond, Audrey ^b,c   Li, Qin ^d   Qin, Chuan ^d   Vital, Anne ^e   Bioulac, Bernard ^e   Gross, Christian E ^e   Wong, Garry ^a   Nahon, Jean Louis ^b,c   Bezard, Erwan ^c,d,e  

^a Department of Pharmacology and Toxicology ^*  (Finland)

^b UNIVERSITÉ CÔTE D'AZUR   (France)

^c CNRS   (France)

^d INSTITUTE OF LABORATORY ANIMAL SCIENCE   (China)

^e UMR 5287   (France)

Author keywords

Brain; Human; Microarray; Monkey; MPTP; Parkinson's disease; Prefrontal cortex; Quantitative PCR

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; RNA;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPSY; BASAL GANGLION; BRAIN REGION; BRAIN TISSUE; CONTROLLED STUDY; DEGENERATIVE DISEASE; FEMALE; GENE CONTROL; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; LOCOMOTION; MACACA; MALE; MICROARRAY ANALYSIS; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; POLYMERASE CHAIN REACTION; PREFRONTAL CORTEX; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANIMALS; DISEASE MODELS, ANIMAL; FEMALE; GLOBUS PALLIDUS; HUMANS; MACACA FASCICULARIS; MALE; MIDDLE AGED; MODELS, NEUROLOGICAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PARKINSON DISEASE; PARKINSONIAN DISORDERS; POLYMERASE CHAIN REACTION; PREFRONTAL CORTEX; PUTAMEN; RNA, MESSENGER; SPECIES SPECIFICITY; THALAMUS;

EID: 77952549129     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2010.02.008     Document Type: Article

References (37)

1. Albin R.L., et al. The functional anatomy of basal ganglia disorders. Trends Neurosci. 1989, 12:366-375.
2. Alexander G.E., et al. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu. Rev. Neurosci. 1986, 9:357-381.
3. Allen S.J., et al. Profound and selective loss of catalytic TrkB immunoreactivity in Alzheimer's disease. Biochem. Biophys. Res. Commun. 1999, 264:648-651.
4. Barraud Q., et al. Sleep disorders in Parkinson's disease: the contribution of the MPTP non-human primate model. Exp. Neurol. 2009, 219:574-582.
5. Bassilana F., et al. Unraveling substantia nigra sequential gene expression in a progressive MPTP-lesioned macaque model of Parkinson's disease. Neurobiol. Dis. 2005, 20:93-103.
6. Bernheimer H., et al. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J. Neurol. Sci. 1973, 20:415-455.
7. Bezard E., Gross C.E. Compensatory mechanisms in experimental and human parkinsonism: towards a dynamic approach. Prog. Neurobiol. 1998, 55:93-116.
8. Bezard E., et al. Involvement of the subthalamic nucleus in glutamatergic compensatory mechanisms. Eur. J. Neurosci. 1999, 11:2167-2170.
9. Bezard E., et al. Structures outside the basal ganglia may compensate for dopamine loss in the pre-symptomatic stages of Parkinson's disease. Faseb J. 2001, 10.1096/fj.00-0637fje.
10. Bezard E., et al. Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive MPTP-lesioned macaque model of Parkinson's disease. J. Neurosci. 2001, 21:6853-6861.
11. Bezard E., et al. Upregulation of striatal preproenkephalin gene expression occurs before the appearance of parkinsonian signs in 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine monkeys. Neurobiol. Dis. 2001, 8:343-350.
12. Bezard E., et al. Presymptomatic compensation in Parkinson's disease is not dopamine-mediated. Trends Neurosci. 2003, 26:215-221.
13. Carbon M., et al. Learning networks in health and Parkinson's disease: reproducibility and treatment effects. Hum. Brain Mapp. 2003, 19:197-211.
14. Dennis G., et al. DAVID: database for annotation, visualization, and integrated discovery. Genome Biol. 2003, 4:P3.
15. Duke D.C., et al. Transcriptome analysis reveals link between proteasomal and mitochondrial pathways in Parkinson's disease. Neurogenetics 2006, 7:139-148.
16. Eidelberg D., et al. The metabolic topography of parkinsonism. J. Cereb. Blood Flow Metab. 1994, 14:783-801.
17. Ferrer I., et al. BDNF and full-length and truncated TrkB expression in Alzheimer disease. Implications in therapeutic strategies. J. Neuropathol. Exp. Neurol. 1999, 58:729-739.
18. Ghorayeb I., et al. A nationwide survey of excessive daytime sleepiness in Parkinson's disease in France. Mov. Disord. 2007, 22:1567-1572.
19. Hirsch E.C., et al. Neuronal vulnerability in Parkinson's disease. J. Neural Transm. 1997, 50:79-88.
20. Huang C., et al. Changes in network activity with the progression of Parkinson's disease. Brain 2007, 130:1834-1846.
21. Israel Z., Bergman H. Pathophysiology of the basal ganglia and movement disorders: from animal models to human clinical applications. Neurosci. Biobehav. Rev. 2008, 32:367-377.
22. Leblois A., et al. Competition between feedback loops underlies normal and pathological dynamics in the basal ganglia. J. Neurosci. 2006, 26:3567-3583.
23. Lohle M., et al. Beyond tremor and rigidity: non-motor features of Parkinson's disease. J. Neural Transm. 2009, 116:1483-1492.
24. Martin R.F., Bowden D.M. A stereotaxic template atlas of the macaque brain for digital imaging and quantitative neuroanatomy. Neuroimage 1996, 4:119-150.
25. Marvanova M., et al. Microarray (comparative genomic) analysis of non human primates: validation of experimental models in neurological disorders. FASEB J. 2003, 10.1096/fj.02-0681fje.
26. Meurers B.H., et al. Dopamine depletion induces distinct compensatory gene expression changes in DARPP-32 signal transduction cascades of striatonigral and striatopallidal neurons. J. Neurosci. 2009, 29:6828-6839.
27. Middleton F.A., Strick P.L. Basal-ganglia 'projections' to the prefrontal cortex of the primate. Cereb. Cortex 2002, 12:926-935.
28. Miller R.M., et al. Dysregulation of gene expression in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-lesioned mouse substantia nigra. J. Neurosci. 2004, 24:7445-7454.
29. Mufson E.J., et al. Loss of basal forebrain P75(NTR) immunoreactivity in subjects with mild cognitive impairment and Alzheimer's disease. J. Comp. Neurol. 2002, 443:136-153.
30. Pfaffl M.W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001, 29:e45.
31. Pifl C., et al. Effect of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine on the regional distribution of brain monoamines in the rhesus monkey. Neuroscience 1991, 44:591-605.
32. Rodriguez-Oroz M.C., et al. Initial clinical manifestations of Parkinson's disease: features and pathophysiological mechanisms. Lancet Neurol. 2009, 8:1128-1139.
33. Roth R.B., et al. Gene expression analyses reveal molecular relationships among 20 regions of the human CNS. Neurogenetics 2006, 7:67-80.
34. Schenck C.H., et al. Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder. Neurology 1996, 46:388-393.
35. Szabo J., Cowan W.M. A stereotaxic atlas of the brain of the cynomolgus monkey (Macaca fascicularis). J. Comp. Neurol. 1984, 222:265-300.
36. Tadaiesky M.T., et al. Emotional, cognitive and neurochemical alterations in a premotor stage model of Parkinson's disease. Neuroscience 2008, 156:830-840.
37. Zigmond M.J., et al. Compensations after lesions of central dopaminergic neurons: some clinical and basic implications. Trends Neurosci. 1990, 13:290-296.